A, Curtis LM. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Renal Physiol 300: F254 -F262, 2011. First published November 3, 2010 doi:10.1152/ajprenal.00594.2010.-Multipotent mesenchymal stem cells (MSC) have become a popular and promising therapeutic approach in many clinical conditions. MSC are beneficial in animal models of acute kidney injury (AKI), by mediating differentiation-independent paracrine properties, and have prompted ongoing clinical trials to evaluate the safety and efficacy of MSC. Heme oxygenase-1 (HO-1) is induced in response to stress including AKI and has important anti-apoptotic, anti-inflammatory, and proangiogenic properties in these settings. We therefore examined whether HO-1 plays a role in the beneficial effects of MSC in AKI. We isolated MSC from bone marrow of age-matched HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ mice. Our studies indicate that while differentiation of MSC into osteo-and adipocytic lineages did not differ between cells isolated from HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ mice, MSC from HO-1 Ϫ/Ϫ mice had significantly lower angiogenic potential. Moreover, HO-1 Ϫ/Ϫ MSC demonstrated reduced expression and secretion of several important growth and proangiogenic factors (stromal cell-derived factor-1, vascular endothelial growth factor-A, and hepatocyte growth factor) compared with MSC derived from HO-1 ϩ/ϩ mice. In addition, conditioned medium of HO-1 ϩ/ϩ MSC rescued functional and morphological changes associated with cisplatin-induced AKI, while the HO-1 Ϫ/Ϫ -conditioned medium was ineffectual. Our studies indicate that HO-1 plays an important role in MSC-mediated protection. The results expand understanding of the renoprotective effects of MSC and may provide novel strategies to better utilize MSC in various disease models. renoprotective effects; multiple organ failure; nephrotoxicity ACUTE KIDNEY INJURY (AKI) is frequently seen in the setting of multiple organ failure in critically ill patients (8, 9) . AKI is an independent risk factor for mortality and morbidity (13). AKI occurs in 1% of hospital admissions and up to 7% of hospitalized patients develop AKI (20). Moreover, ϳ25% of patients in the intensive care unit (ICU) develop AKI and 5% of the patients in the ICU require renal replacement therapy (20, 43) . Despite fundamental advances in understanding the pathophysiology of AKI, definitive therapies remain limited. These approaches mainly include attempting to correct the underlying cause of AKI and supportive care. Such limitations in the context of AKI therapy have translated into high mortality rates of ϳ45% in affected patients (6, 25) . There is an alarming increase in the incidence of AKI that has been attributed to several factors including shifts in patient demographics (older, more comorbid illness), severity of illness (multiple organ dysfunction syndrome), and AKI associated with complex interventions (organ transplantation) (7). The consequence of such a rise in the number of patients suffering from AKI has an evident and devastating effect on public health and resources and is a substantial economic burden (42). Hence, it is imperative to accelerate the understanding of underlying causes of AKI and to develop new interventional and therapeutic modalities.
renoprotective effects; multiple organ failure; nephrotoxicity ACUTE KIDNEY INJURY (AKI) is frequently seen in the setting of multiple organ failure in critically ill patients (8, 9) . AKI is an independent risk factor for mortality and morbidity (13) . AKI occurs in 1% of hospital admissions and up to 7% of hospitalized patients develop AKI (20) . Moreover, ϳ25% of patients in the intensive care unit (ICU) develop AKI and 5% of the patients in the ICU require renal replacement therapy (20, 43) . Despite fundamental advances in understanding the pathophysiology of AKI, definitive therapies remain limited. These approaches mainly include attempting to correct the underlying cause of AKI and supportive care. Such limitations in the context of AKI therapy have translated into high mortality rates of ϳ45% in affected patients (6, 25) . There is an alarming increase in the incidence of AKI that has been attributed to several factors including shifts in patient demographics (older, more comorbid illness), severity of illness (multiple organ dysfunction syndrome), and AKI associated with complex interventions (organ transplantation) (7) . The consequence of such a rise in the number of patients suffering from AKI has an evident and devastating effect on public health and resources and is a substantial economic burden (42) . Hence, it is imperative to accelerate the understanding of underlying causes of AKI and to develop new interventional and therapeutic modalities.
An approach that has sparked great interest and gained enormous popularity in recent years is the utilization of mesenchymal stem cells (MSC) to treat AKI and other acute clinical conditions (11, 34, 38) . MSC are versatile and multipotent cells that can be isolated from several tissues and expanded ex vivo (29) . Growing evidence demonstrates the anti-inflammatory, reparative, and immunomodulatory properties of these cells (15, 21) . MSC are known to home to the site of injury and exert their beneficial effects by secreting important angiogenic and reparative cytokines and growth factors (34, 37) . Several animal models have already demonstrated the protective effects of MSC (4) and in fact there is an ongoing clinical trial evaluating the safety and efficacy of MSC in cardiac surgery-related AKI (clinicaltrials.gov, NCT00733876).
Another potential approach to overcome AKI is to employ inducible anti-oxidant enzymes such as heme oxygenase-1 (HO-1) (2, 40) . HO-1 is a stress-responsive enzyme that has important anti-inflammatory and anti-apoptotic properties that are attributed to its byproducts (24) . HO-1 catalyzes the ratelimiting step in the oxidative degradation of cellular heme that liberates equimolar amounts of iron, carbon monoxide, and biliverdin (24) . This reaction eliminates the prooxidant heme and prevents it from sensitizing cells to undergo programmed cell death. The biological functions of HO-1 have been studied extensively in various in vitro and animal models of injury (1) . Moreover, its indispensable nature was also highlighted in a case report that described a patient with HO-1 deficiency who exhibited several pathological phenotypes, including hematuria, proteinuria, hyperlipidemia, iron deposition in the kidney, hemolysis, vasculopathy, and renal interstitial fibrosis (46) . In this study, we investigated the possible role of HO-1 in the protective effects of MSC. To accomplish this goal, we used MSC harvested from HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ mice and examined their differentiation capacity as well as paracrine properties in vitro and in vivo in cisplatin-induced nephrotoxicity. Soleimani and Nadri (32) with some minor modifications. Briefly, mice were killed by cervical dislocation and their femurs were carefully cleaned from adherent soft tissue. The tip of each bone was removed and the marrow was harvested by inserting a syringe needle (18-gauge) into one end of the bone and flushing with MSC expansion medium supplemented with 20% FBS (Cellgro, Manassas, VA), 4 mM glutamine, and 10 ml/l of antibiotic/antimycotic (ABAM, GIBCO, Carlsbad, CA). The cells were filtered through a 70-m filter mesh to remove any bone spicules, muscle, or cell clumps. The cells were then cultured in a T-25 flask in complete media. After 24 h, the nonadherent cells were removed by changing the medium and replacing with fresh complete medium. Thereafter, the media was changed every 3-4 days. After 4 -6 wk of culture, primary cells were nearly confluent and the culture was passaged by trypsinization (1.5 ml of 0.25% trypsin containing 0.02% ethylenediaminetetraacetic acid; Invitrogen, Carlsbad, CA) for 2 min at room temperature (25°C). All cells used in these studies were from passages 2-5. Flow cytometry. Cells were washed once with cold PBS and incubated for 10 min at room temperature with anti-mouse CD16/32 to block nonspecific binding to FC␥3 receptors. Cells were then stained with PE-conjugated anti-CD34 and APC-conjugated anti-CD45 for 30 min on ice. 7-Amino-actinomycin-D was used for live/dead cell discrimination. PE-and APC-conjugated, isotypematched antibodies of irrelevant specificity were used as controls. All antibodies were purchased from eBioscience (San Diego, CA). Data acquisition was performed on a FACSCalibur flow cytometer (BD Biosciences, Bedford, MA) and results were analyzed using Winlist 6.0 software (Verity software house, Topsham, MA).
MATERIALS AND METHODS

Culture
Differentiation of MSC. Osteoblastic differentiation was induced by culturing confluent mouse MSC for 3 wk in MSC expansion medium supplemented with 10 Ϫ8 M dexamethasone, 2.5 mM inorganic phosphate, and 0.3 mM ascorbic acid. Cells were maintained in osteoinductive medium for 3 wk with a daily change in medium to overcome the instability of ascorbic acid at a neutral pH. Mineralization was determined by alizarin red staining. To induce adipocytic differentiation, confluent MSC were cultured from 2 to 3 wk in MSC expansion medium supplemented with 10 Ϫ8 M dexamethasone and 0.5 g/ml insulin. Cells were used for lipid droplet staining using oil red. To induce chondrocytic differentiation, trypsinized MSC were rinsed once by centrifugation, resuspended in chondrogenic medium, and finally centrifuged for 5 min at 350 g to form a pellet. Chondrogenic medium consisted of MSC expansion medium supplemented with 10 Ϫ7 M dexamethasone, 1 mM sodium pyruvate, 1.7 ϫ 10 Ϫ4 M 2-phosphate ascorbic acid, 35 mM proline and insulin, transferrin, selenium. Medium was changed every 3-4 days for 3 wk before toluidine blue staining was performed. To assess the endothelial differentiation potential of MSC, an equal number of cells/well were seeded onto 96-well plates coated with growth factor-reduced matrigel (BD) and incubated in endothelial basal media-2 (EBM-2; Lonza, Walkersville, MD) for 9 days. The media was changed every 3-4 days.
Western blot analysis and ELISA. Immunoblot analysis was performed as described previously (10) . Briefly, cell cultures and tissues were lysed in RIPA buffer, electrophoresed in a 12% SDS-polyacrylamide gel, and transferred onto a Hybond C Extra membrane (Amersham Biosciences, Piscataway, NJ). Membranes were incubated with anti-HO-1 (1:5,000 dilution; Stressgen, San Diego, CA), anticleaved caspase-3 (1:1,000 dilution; Cell Signaling, Danvers, MA), or anti-stromal-derived factor-1␣ (SDF-1; 1:500 dilution; Millipore, Billerica, MA) antibodies, followed by a peroxidase-conjugated goat anti-rabbit IgG antibody (1:10,000 dilution; Jackson ImmunoResearch Laboratories, Grove, PA). Horseradish peroxidase activity was detected using enhanced chemiluminescence. The membrane was stripped and probed with anti-actin antibody (1:5,000 dilution) to confirm loading and transfer. Enzyme-linked immunosorbent assay (ELISA) analyses for SDF-1, vascular endothelial growth factor (VEGF-A), and hepatocyte growth factor (HGF; R&D, Minneapolis, MN) were performed following the manufacturer's instructions.
Real-time PCR analysis. RNA was isolated from cells using TRIzol (Invitrogen) according to the manufacturer's protocol. Three micrograms of RNA were used to convert to cDNA using the First Strand cDNA Synthesis Superscript kit (Invitrogen) according to the manufacturer's protocol. Quantitative real-time PCR was performed with SYBR Green Mastermix (Invitrogen) and 15 pmol primers for mouse SDF-1, VEGF-A, HGF, and GAPDH. Reactions were performed in triplicate and specificity was monitored using melting curve analysis after cycling. Primers used were as follows: forward (5=-GTCCTCT-TGCTGTCCAGCTC-3=) and reverse (5=-AGATGCTTGACGTTG-GCTCT-3=) for SDF-1␣, forward (5=-AGAGCAACATCACCATG-CAG-3=) and reverse (5=-CAGTGAACGCTCCAGGATTT-3=) for VEGF-A, forward (5=-AGGAACAGGGGCTTTACGTT-3=) and reverse (5=-GCTGCCTCCTTTACCAATGA-3=) for HGF, and forward (5=-ATCATCCCTGCATCCACT-3=) and reverse (5=-ATCCAC-GACGGACACATT-3=) for GAPDH. Relative mRNA expression was quantified using the ⌬⌬Ct method and GAPDH was used as an internal control.
Cisplatin injury model. Male HO-1 ϩ/ϩ mice (10 to 14 wk of age) were administered 20 mg/kg body wt cisplatin (1.0 mg/ml solution in sterile 0.9% NaCl) by a single intraperitoneal injection. The animals were then divided into three groups and 6-h postcisplatin administration as follows: group 1 received serum-free medium (SFM), group 2 received HO-1 ϩ/ϩ -conditioned medium (CM), and group 3 received ϩ/ϩ and HO-1 Ϫ/Ϫ mice were cultured in osteoblastic medium for 2 wk and alizarin red staining was used to visualize calcium deposition (top). Confluent isolated cells were treated with adipogenic medium for 2-3 wk and oil red was used to stain the lipid droplets (middle). An equal number of cells were placed on growth factor-reduced matrigel and cultured in endothelial basal medium-2 for 9 days (bottom). The figure shows representative images of 3 separate experiments. Bar ϭ 100 m.
HO-1
Ϫ/Ϫ CM. The CM was concentrated 10 times by ultrafiltration using centrifugal filter units with a 5-kDa cut-off (Millipore) as indicated in the manufacturer's instructions. A final volume of 200 l was administered by a single intraperitoneal injection 6 h after cisplatin injection. All animals were killed 72 h after cisplatin administration. Blood was collected via heart puncture and serum was isolated for creatinine determination. Serum creatinine concentration was determined using LC-MS/MS, as previously described (33) .
Histological assessment. At 72 h after cisplatin administration, the animals were killed under anesthesia and their organs were harvested as detailed below. The kidneys were removed and cut transversally into three equal sections. The middle section was immersed in 10% formalin for 24 h and then transferred into 70% ethanol. These tissues were embedded in paraffin and 5-m sections were stained with periodic acid-Schiff. The remaining two kidney pieces were snapfrozen for apoptosis evaluation. Morphological assessment of injury was determined in the cortex and outer medulla by counting the number of tubules exhibiting loss of brush border, necrosis, and cast formation from 20 high-power fields/animal in a blinded fashion.
Hypoxic exposure. O 2 at a concentration of 1% in compressed air was mixed with compressed air containing 5% CO 2 and ϳ94% nitrogen before being delivered into the culture incubator. The incubator was humidified and maintained at 37°C. An O 2 analyzer was used to determine O 2 levels in the chamber. Once the chamber was stabilized, no oscillations were measured in the O 2 concentration.
Statistical analysis. Data are presented as means Ϯ SE. The t-test was used for comparisons between two groups. For the comparisons that involved more than two groups, ANOVA and the Newman-Keuls test were used for analysis, with statistical significance considered at P Ͻ 0.05.
RESULTS
MSC isolation, characterization, and differentiation. Successful isolation and expansion of MSC from mouse bone marrow were confirmed by two methods. First, the expanded cells showing spindle-shaped morphology were trypsinized and evaluated for absence of hematopoietic markers. FACS analysis demonstrated that the cultures were entirely negative for CD34 and CD45, which are two specific markers of hematopoietic cells (Fig. 1A) . To confirm the viability of the tested cells, we used the 7-aminoactinomycin D, a marker that can only bind to DNA if the cell membranes are disrupted (Fig.  1A) . To validate the pluripotential capacity of the cultured cells, we verified their differentiation along the osteoblastic, adipocytic, and chondrocytic lineages (Fig. 1B) . These results confirmed the purity and the pluripotential nature of the cells in culture.
HO-1 is essential for the angiogenic potential of MSC.
To examine the possible role of HO-1 in MSC differentiation, we cultured HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ MSC in specific media. After 3 wk of culture, alizarin red stain was used to evaluate the extracellular calcium deposition; we did not find any major differences between the two groups (Fig. 2, top) . Next, we cultured the cells in adipoinductive media for 2 wk and used oil red to stain the lipid droplets. We found that cells from both groups were equally capable of differentiating into adipocytes (Fig. 2, middle) . We then compared the angiogenic potential of HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ MSC. For this purpose, we placed an equal number of cells/well on growth factor-reduced matirgel and cultured the MSC with EBM-2 supplemented with all the requirements for angiogenesis, including VEGF-A. HO-1
MSC demonstrated a significantly lower number of capillarylike projections after 9 days of culture than their HO-1 ϩ/ϩ counterparts (Fig. 2, bottom) .
Hypoxia stimulates HO-1 expression in HO-1 ϩ/ϩ MSC. Two lines of evidence led us to ask whether SDF-1 may be involved in the higher angiogenic potential of HO-1 ϩ/ϩ compared with HO-1 Ϫ/Ϫ MSC (Fig. 2, bottom) : 1) our previous findings that revealed the essential role of HO-1 in support of SDF-1 function in endothelial progenitor cells (10) and 2) the importance of SDF-1 in the beneficial effects of MSC in AKI (36) . Confluent cells were exposed to 1% O 2 and cell lysates were harvested at the indicated time points. Our data demonstrate that HO-1 upregulation is seen after hypoxic treatment in HO-1 ϩ/ϩ MSC but as expected not in HO-1 Ϫ/Ϫ cells (Fig. 3) . HO-1 is required for growth factor secretion by MSC. It is well-recognized that MSC secrete several different growth factors that are essential in angiogenesis and repair processes. ϩ/ϩ and HO-1 Ϫ/Ϫ cells were cultured in SFM and were incubated in normoxic conditions or exposed to 1% O2. After 24 h, the conditioned medium (CM) was collected and used to quantify the level of SDF-1 (A), VEGF-A (B), and HGF (C) secretion using a "sandwich" ELISA method as described in MATERIALS AND METHODS. The results were normalized to the total protein content and expressed as means Ϯ SE. Data represent results from 4 to 10 independent experiments. *P Ͻ 0.05.
To examine the role of HO-1 in secretion of such growth factors, we cultured confluent cells in SFM and incubated them either in normoxic or hypoxic conditions for 24 h. We then collected the CM and tested for the amount of growth factors using ELISA. We demonstrated that HO-1 Ϫ/Ϫ cells secrete substantially lower amounts of SDF-1 (Fig. 4A ) and VEGF-A (Fig. 4B ) when exposed to hypoxia for 24 h compared with HO-1 ϩ/ϩ MSC. It is well-known that the expression of these two growth factors is increased by hypoxic conditions (5, 39) . To examine whether the increased expression and secretion of growth factors by HO-1 ϩ/ϩ cells are solely dependent on their response to hypoxia, we also tested for another growth factor, HGF, the baseline expression and induction of which are not directly modulated by hypoxia. Our results indicate that the levels of HGF secretion were lower in HO-1 Ϫ/Ϫ cells under normoxic as well as hypoxic conditions compared with their HO-1 ϩ/ϩ counterparts (Fig. 4C) . To investigate the role of HO-1 in the context of MSC growth factor expression, we exposed confluent MSC to 8 h of hypoxia and examined the mRNA levels of SDF-1 (Fig. 5A) , VEGF-A (Fig. 5B) , and HGF (Fig. 5C ) in both groups of cells. Accordingly, we detected significantly lower mRNA levels of these growth factors in HO-1 Ϫ/Ϫ MSC. To corroborate these findings and to further clarify the role of HO-1, we exposed both groups of cells to different periods of hypoxia and examined their growth factor mRNA levels. HO-1 ϩ/ϩ MSC demonstrated a more robust response to hypoxia by increasing their SDF-1 (Fig. 5D ) and VEGF-A (Fig. 5E ) transcription. The peak of such response was observed at 8 h for SDF-1 and at 4 h for VEGF-A. On the other hand, while HO-1 Ϫ/Ϫ MSC express significantly lower levels of HGF mRNA compared with HO-1 ϩ/ϩ MSC, such lower levels were not significantly modulated by hypoxic exposure (Fig. 5F) in HO-1 Ϫ/Ϫ MSC.
Effects of MSC CM on cisplatin-induced AKI requires HO-1.
We then asked whether our in vitro findings could be implemented in vivo to offer protection against AKI. Since the beneficial effects of MSC are in fact influenced by their paracrine actions, we used concentrated CM from HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ MSC for comparison in a cisplatin model of AKI. We administered concentrated CM at 6-h postcisplatin administration and killed the animals at 72-h postcisplatin administration. While the HO-1 Ϫ/Ϫ CM was completely ineffectual, HO-1 ϩ/ϩ CM prevented the decline in body weight (Fig. 6A ) and the rise in serum creatinine concentration (Fig.  6B ). We also examined the level of induction of apoptosis 72 h after cisplatin administration and observed that while administration of HO-1 Ϫ/Ϫ CM was not protective and showed increase in cleaved caspase-3 activation, levels of cleaved caspase-3 were almost undetectable in the kidney of mice treated with HO-1 ϩ/ϩ CM (Fig. 6C) . HO-1 ϩ/ϩ CM improves renal recovery and histology following cisplatin-induced AKI. Histological analysis of kidneys to assess the severity of renal structural injury among different treatment groups showed that cisplatin causes significant structural damage in animals that received the control SFM. This was illustrated by the presence of casts within the tubules, necrotic tubules, and the loss of brush-border staining (Fig. 7A,  left) . No significant differences were observed between the animals that were treated with HO-1 Ϫ/Ϫ CM (Fig. 7A, right ) and SFM. On the other hand, the structural damage was reversed in animals that were treated with HO-1 ϩ/ϩ CM (Fig.  7A, middle) . Quantitative analysis of renal injury using the extent of cast formation, loss of brush border, and necrotic tubules (Fig. 7B ) demonstrated the lack of protection by CM from HO-1 Ϫ/Ϫ MSC.
DISCUSSION
The present study demonstrates that while differentiation of MSC into osteo-and adipocytic lineages is not modulated by HO-1, angiogenic potential of MSC requires HO-1. In addition, we provide evidence that HO-1 regulates growth and reparative factor expression and secretion by MSC in response to hypoxia. Moreover, we corroborate previous findings of the paracrine-dependent protective effects of MSC and demonstrate for the first time that such effects require HO-1.
The first description that a small fraction of cells in the bone marrow were capable of binding to culture surfaces and had the capacity to differentiate into diverse cell types was published more than 20 years ago (26) . These observations were later confirmed by numerous investigators. MSC have now been successfully isolated and cultured from various tissues including bone marrow, adipose tissue, skeletal muscle, periosteum, trabecular bone, synovium, and even deciduous teeth (29, 30) . Such ability of these cells to expand in vitro and differentiate into multiple cell lineages was the main factor that led to the hypothesis that MSC may be utilized to provide protection in pathological conditions by engrafting and replacing necrotic cells in damaged tissues. These aspects created an enormous interest in studies to elucidate the beneficial role(s) of MSC and their utilization in different clinical settings. The protective properties of MSC have now been confirmed in a number of pathophysiologically distinct conditions including neuronal repair, myocardial infarction, lung and liver injury models, autoimmune diseases, sepsis, and AKI (28) .
Although it was shown that following administration, MSC home to the site of injury, there was little evidence supporting their differentiation and actual engraftment into the injured tissues (22) . One of the earliest observations suggesting alternative mechanisms other than differentiation and replacement was from a study that detected Ͻ1% of donor MSC in children with osteogenesis imperfecta who had received MSC (17) . More recent evidence suggests that protection from injury can be achieved in the absence of stem cell differentiation, thereby suggesting that stem cells facilitate regeneration and repair of native cells via cell-cell interactions or via the release of protective paracrine substances during their transit through injured tissue (3, 22, 35, 37) . In fact many investigators showed that MSC actively secrete several essential growth factors including SDF-1, VEGF-A, and HGF (14, 37, 44, 45) . Such dynamic secretion of these growth factors implies that MSC can aid in regeneration and repair of the injured tissue by promoting angiogenesis, preventing apoptosis, and stimulating native cell proliferation.
Both MSC and HO-1 have been shown to be protective in different models of AKI including rhabdomyolysis, ischemiareperfusion, and cisplatin-mediated injury (16, 18, 23, 37) . Furthermore, previous studies demonstrated that HO-1 overexpression in MSC enhances their protective effects and increases survival in myocardial ischemia and cardiac transplant models (19, 41, 47) . We were intrigued to find that while there was no major difference between HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ MSC with regard to adipo-and osteogenesis, HO-1 Ϫ/Ϫ MSC had significantly lower angiogenic and growth factor secretion potential. In response to hypoxia, HO-1 Ϫ/Ϫ MSC produced significantly lower levels of SDF-1 and VEGF-A, which are two key regulators of angiogenesis and repair and they are both robustly induced by hypoxia. To answer whether deficiency of HO-1 is only limited to cytokines that are directly controlled by hypoxia, we examined another growth factor (HGF) that is not directly regulated by hypoxic conditions. Intriguingly, we observed that HO-1 is also required for HGF secretion. The mechanism for the lack of protection by CM from HO-1 Ϫ/Ϫ MSC is most likely related to lower levels of key molecules such as SDF-1, VEGF-A, and HGF. However, it is possible that other mediators may also be involved that require further elucidation. Nonetheless, our findings may explain the increased susceptibility of HO-1 Ϫ/Ϫ animals to different injury models where MSC are important protective mediators including ischemia-reperfusion, rhabdomyolysis, and cisplatin-induced nephrotoxicity.
In conclusion, the absence of HO-1 expression in MSC limits their protective paracrine effects as well as their therapeutic potential in cisplatin-induced AKI. The data further corroborated the seminal therapeutic role of the paracrine activity of MSC in AKI. Recent studies investigated the po- tential link between HO-1 polymorphisms in humans and outcomes in clinical settings including vascular stenosis, arteriovenous fistula, and renal transplantation as well as others (12, 27, 31) . These studies concluded that shorter guanosinethymidine nucleotide repeats in the HO-1 promoter are associated with better patient outcome and lower mortality rates. The finding that HO-1 expression influences the therapeutic effects of MSC is particularly germane and of relevance to ongoing clinical trials that are evaluating the efficacy of MSC in multiple conditions including AKI (clinicaltrials.gov, NCT00733876). In addition to other criteria, screening donors for HO-1 polymorphism and subsequent level of expression might ensure the utmost therapeutic potential of MSC.
